VaxNet Finishes “Highly Recommended” in Best Clinical Trial Site Network Category at the 2012 Vaccine Industry Excellence Awards

VaxNet has been recognized in the Best Clinical Trial Site Network category at the 2012 Vaccine Industry Excellence awards.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“VaxNet is honored to have been nominated among such a stellar group of site networks, and we are thrilled to have been highly recommended by the panel of judges for this award,” said Mark Lacy, CEO of Benchmark Research

Washington, D.C. (PRWEB) April 24, 2012

VaxNet, a network of independently owned, geographically diverse research sites that specialize in multi-therapeutic vaccine trials, has been recognized as the “highly recommended” runner-up in the Best Clinical Trial Site Network category at the 2012 Vaccine Industry Excellence awards. The awards ceremony, held during the Annual World Vaccine Congress, recognized Benchmark Research, Meridian Clinical Research and Regional Clinical Research – collectively VaxNet – for outstanding performance and development of internal quality control measures for industry sponsored vaccine trials.

“VaxNet is honored to have been nominated among such a stellar group of site networks, and we are thrilled to have been highly recommended by the panel of judges for this award,” said Mark Lacy, CEO of Benchmark Research. VaxNet was specifically acknowledged for the development of several internal quality measures created to provide ongoing feedback to clients. Meridian Clinical Research CEO Nicole Osborn added, “The internal quality initiatives VaxNet developed in the third quarter of 2011 have been created with our strategic partners to provide consistency among our sites and have added a higher level of insight into the conduct of our vaccine programs.”

VaxNet’s clients value the geographic distribution and demographic diversity of the sites within the network; covering Upstate New York, Nebraska, South Dakota, Texas, Louisiana and California. Having successfully completed more than 225 trials, which have enrolled more than 25,000 study participants, VaxNet offers immediate access to sites that can effectively meet and exceed enrollment goals without sacrificing quality. “VaxNet’s consistent, long-standing track record of performance and our One Voice Concept have allowed our network to expand our client base and forge strategic partnerships with more sponsor and CRO clients,” noted Debra Gabrielson, CEO of Regional Clinical Research.

For more information about how VaxNet can help you accomplish your vaccine study goals, please contact:

Andrew Kimball
Director of Research and Development
(469) 854-0294
andrewkimball(at)benchmarkresearch(dot)net


Contact

  • Andrew Kimball
    andrewkimball@benchmarkresearch.net
    469-854-0294
    Email